IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

FARINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.370
NA - Nord America 4.535
AS - Asia 4.081
SA - Sud America 496
AF - Africa 121
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 10
Totale 14.631
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.354
GB - Regno Unito 1.508
CN - Cina 1.498
SG - Singapore 1.266
IT - Italia 768
DE - Germania 716
SE - Svezia 696
RU - Federazione Russa 388
BR - Brasile 375
HK - Hong Kong 357
NL - Olanda 283
IN - India 274
TR - Turchia 215
UA - Ucraina 207
FR - Francia 185
IE - Irlanda 146
KR - Corea 146
FI - Finlandia 138
CA - Canada 130
EU - Europa 118
PL - Polonia 98
VN - Vietnam 65
ID - Indonesia 58
CO - Colombia 54
CI - Costa d'Avorio 53
JP - Giappone 44
BE - Belgio 41
GR - Grecia 39
MX - Messico 35
DK - Danimarca 27
ES - Italia 27
AR - Argentina 24
CH - Svizzera 22
RO - Romania 22
ZA - Sudafrica 18
BD - Bangladesh 16
IQ - Iraq 16
AU - Australia 14
IR - Iran 13
TW - Taiwan 13
UZ - Uzbekistan 13
AT - Austria 12
IL - Israele 12
MY - Malesia 11
PY - Paraguay 11
MA - Marocco 10
EG - Egitto 9
KE - Kenya 9
PK - Pakistan 9
PE - Perù 8
PH - Filippine 8
SA - Arabia Saudita 7
AL - Albania 6
EC - Ecuador 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
CZ - Repubblica Ceca 5
LB - Libano 5
TN - Tunisia 5
BG - Bulgaria 4
JM - Giamaica 4
KZ - Kazakistan 4
LT - Lituania 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
UY - Uruguay 4
AZ - Azerbaigian 3
BO - Bolivia 3
DZ - Algeria 3
HR - Croazia 3
JO - Giordania 3
LU - Lussemburgo 3
NP - Nepal 3
PS - Palestinian Territory 3
PT - Portogallo 3
SC - Seychelles 3
TT - Trinidad e Tobago 3
XK - ???statistics.table.value.countryCode.XK??? 3
BH - Bahrain 2
HN - Honduras 2
KG - Kirghizistan 2
LY - Libia 2
NG - Nigeria 2
PA - Panama 2
RS - Serbia 2
SI - Slovenia 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BJ - Benin 1
BM - Bermuda 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
Totale 14.728
Salva come PNG Salva come JPEG
Città #
Southend 1.356
Singapore 662
Ashburn 432
Chandler 420
Beijing 363
Hong Kong 346
Milan 284
Seattle 246
Princeton 204
Wilmington 193
Dallas 190
Jacksonville 149
Council Bluffs 142
Dublin 142
Frankfurt am Main 141
Ann Arbor 121
Mountain View 121
Redmond 112
Nanjing 111
Bengaluru 109
Los Angeles 104
Fairfield 103
Santa Clara 101
Munich 89
Warsaw 88
Toronto 86
Boardman 84
Phoenix 80
Sakarya 73
Woodbridge 72
Dearborn 66
Shanghai 63
Des Moines 62
Buffalo 58
Medford 56
Abidjan 53
Serra 53
Moscow 52
Andover 49
Hefei 49
São Paulo 48
Bogotá 46
New York 46
Helsinki 42
Somerville 40
Shenyang 39
Guangzhou 38
Jakarta 38
Cambridge 36
San Jose 35
Athens 34
Houston 34
Jinan 34
Brussels 32
Changsha 32
Nanchang 32
Eitensheim 30
Redwood City 30
Tianjin 29
Tokyo 29
Cangzhou 28
Columbus 28
Rome 27
San Diego 24
Sunnyvale 24
London 23
Berlin 22
Hamburg 21
Ho Chi Minh City 21
Odernheim 21
Chicago 20
Hebei 20
Zhengzhou 20
Hanover 19
Mumbai 19
Nuremberg 19
The Dalles 19
Fuzhou 18
Hangzhou 18
Quanzhou 18
Roxbury 18
Bitonto 17
Hanoi 15
Ottawa 14
Seoul 14
Wuhan 14
Turin 13
Grafing 12
Haikou 12
Falkenstein 11
Kiez 11
Falls Church 10
Jiaxing 10
Kunming 10
Norwalk 10
Nürnberg 10
Paris 10
Rio de Janeiro 10
Amsterdam 9
Boston 9
Totale 8.677
Salva come PNG Salva come JPEG
Nome #
Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle 331
CD133+ cells isolated from various sources and their role in future clinical perspective 317
Modificazione genica di cellule staminali distrofiche allo scopo di trapianto autologo nella distrofia muscolare di Duchenne 297
Blockade of IGF2R improves muscle regeneration and ameliorates Duchenne muscular dystrophy 288
Preliminary evidences of safety and efficacy of flavonoids- and omega 3-based compound for muscular dystrophies treatment: a randomized double-blind placebo controlled pilot clinical trial. 246
T and b lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse 245
Expression of CD20 reveals a new store-operated calcium entry modulator in skeletal muscle 234
Exome sequencing identifies variants in two genes encoding the LIM-proteins NRAP and FHL1 in an Italian patient with BAG3 myofibrillar myopathy 225
Characterization of muscle-specific expression of miRNAs in duchenne muscular dystrophy 224
Skin-derived stem cells transplanted into resorable guides provide functional nerve regeneration after sciatic nerve resection 216
Correlation of circulanting CD133+ progenitor subclasses with a Mild phenotype in Duchenne Muscular dystrophy patients 214
Morphological modifications of resected sciatic nerve after autologous transplantation of skin-derived stem cells into resorable guides. 213
Combining Stem Cell and Exon Skipping Approach to Treat Muscular Dystrophies 212
Advancements in stem cells treatment of skeletal muscle wasting 211
Stem cells and muscular dystrophies 210
Abundance of circulating progenitors with myo-endothelial potential correlates with a mild phenotype in patients affected by Duchenne muscular dystrophy 204
VCAM-1 expression on dystrophic muscle vessels has a critical role in the recruitment of human blood-derived CD133+ stem cells after intra-arterial transplantation 197
Microbiota dysbiosis influences immune system and muscle pathophysiology of dystrophin‐deficient mice 196
CD20-related signaling pathway is differently activated in normal and dystrophic circulating CD133+ stem cells 196
Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model 188
Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect 179
Impact of Muscular Dystrophy on the Regenerative Properties of interstitial Muscle Cells 177
Cell Therapy of Muscular Dystrophy with Engineered CD133+ Cells 176
Perspectives of Stem Cell Therapy in Duchenne Muscular Dystrophy 176
Defective dystrophic thymus determines degenerative changes in skeletal muscle 176
Development of a new technique for muscle tissues-stem cells co-colture 175
Cell Theraphy of Muscolar Dystrophy with Engineered CD133+Cell 174
Skin-derived stem cells transplanted into resorbable guides provide functional nerve regeneration after sciatic nerve resection 169
MicroRNA-206 is upregulated in an animal model of Duchenne Muscular Distrophy 169
Differential Activativation of CD20-Related Signalling Pathway Results in Distinct Differentiation Behaviour of Normal and DMD Circulating CD133+ Stem Cells 169
Combining Gene and Stem Cell therapy in the Treatment of Dysferlinophaties 168
In Vivo Tracking of Stem cell by Nanotechnologies : Future Prospect for Mouse to Human Translation 168
The myomiR-206 partecipate to muscle-regeneration by sculpting the chromatin through the down.regulation of the non-histone chromatin-associated protein High Mobility group protein 3 (Hmgb3) 167
The role of stem cells in muscular dystrophy 165
Preclinical experience and perspectives of a clinical trial using cD133 stem cells 165
Combining stem cells and exon skipping strategy to treat muscular dystrophy 162
Combining gene and stem cell therapy in the treatment of disferlinopaties 161
MicroRNA-206 is upregulated in an animal model of Duchenne Muscular Distrophy. 160
Development of new technologies Including myogenic differentiation of human circulating CD133+cells 160
Hmgb3 Is Regulated by MicroRNA-206 during Muscle Regeneration 157
Muscle-specific microRNAs (mirnas) in Duchenne Muscular Distrophy (DMD). 156
Absence of T and B lymphocytes modulates dystrophic features in dysferlin deficient animal model 155
Cell Based Therapy for Duchenne Muscular Dystrophy 154
Absence of T and B lymphocytes enhances skeletal muscle regeneration and ameliorates dystrophic pathology in dysferlin deficient animal model 154
Ex vivo expansion of human circulanting CD133+promising tool for cell-based therapeutic approaches in muscular dystrophy 153
Differential Activation of CD20-related Signaling Pathways Results in distinct differentiation behaviour of normal and DMD circulating CD133+ Stem Cells 153
Muscular dystrophies therapies by engineered stem cells 153
Ex vivo expansion of human circulating CD133+ progenitors cells: promising tool for cell-based therapeutic approaches in muscular dystrophy. 152
Myogenic differentiation potential of CD133+ stem cells isolated from various sources 152
Exon-skipping of dysferlin in CD133+ stem cells isolated from normal and patient affected with dysferlinopathies. 150
In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled CD133+ stem cell tropism to dystrophic muscle tissues using micro-CT imaging 150
CD133+ Cells for the Treatment of Degenerative Diseases : update and perspectives 150
Stem Cell Therapies to Treat Muscular Dystrophy : Progress to Date 149
Ex vivo expansion of peripheral blood CD133+ progenitors cells: promising tool for cell-based therapeutic approaches in muscular dystrophy. 147
Combining Stem Cells and Exon-Skipping and Approch to Treat Muscular Dystrophies 146
Autologous transplantation of engineered muscle-derived CD133+ stem cells 145
Role of Insulin-Like Growth Factor Receptor 2 across Muscle Homeostasis: Implications for Treating Muscular Dystrophy 145
Mesenchymal Stem Cells as Muscle Reservoir 142
Abundance of Circulating Progenitors with Myo-Endothelial Potential Correlates with a Mild Phenotype in Patients Affected by Duchnne Muscular Dystrophy 142
MiRNAs dysregulation of Single Muscle Fibers in Duchenne Muscular Dystrophy 140
Proliferation and Clonal Analysis of Muscle Derived CD133+ Stem Cell Subpopulations Define a Depletion of Mesenchymal Population in DMD Patients 137
Perturbation of calcium handling in CD133+ stem cells isolated from DMD blood 136
Proliferation and clonal characterization of human muscle derived CD133+ positive stem cells define an intrinsic heterogeneity 136
Rescue of human dystrophin after transplantation of exon-skipping-engineered DMD stem cells in a dystrophic animal model 135
Full-length dysferlin expression driven by engineered human dystrophic blood-derived CD133+ stem cells 135
Human Fetal CD133+ Muscle Cells Expressing Perycite Markers Repair Dystrophic Muscle Tissue. 132
Cell replacement therapy in neuromuscular and neurodegenerative diseases 132
Inhibition of the immunoproteasome modulates innate immunity to ameliorate muscle pathology of dysferlin-deficient BlAJ mice 132
Stem cell therapy of muscular dystrophies using exon skipping approach in GRMD dogs 130
Stem cell-mediated exon skipping of the dystrophin gene by the bystander effect 128
Perturbation of calcium handling in CD133+ stem cells isolated from DMD blood 126
Restoration of human dystrophin following transplantation of exon-skipping-engineered DMD patient stem cells into dystrophic mice 126
Proliferation and clonal Characterization of Human Muscle Derived CD133+ Stem Cell Define an Intrinsic Heterogeneity 126
MicroRNA-206 is Upregulated in an Animal Model of Duchenne Muscular Dystrophy 126
Réhabilitation de la dystrophine humaine dans le modèle scid/mdx après greffe de cellules souches de patients DMD corrigées par saut d’exon 125
Exon-Skipping of Dysferlin in CD133+ Stem Cells Isolated from normal and patient affected with Dysferlinopathies 125
Multifaceted nanoparticles: emerging mechanisms and therapies in neurodegenerative diseases 122
MiRNAs Dysregulation of Single muscle fibers in Duchenne Muscular Dystrophy 121
Improvement of endurance of DMD animal model using natural polyphenols 119
Proliferation and Clonal Characterization of Human muscle Derived CD 133+ stem cell Define an Heterogeneity 116
Ex vivo expansion of human circulating myogenic progenitors on cluster-assembled nanostructured TiO2 115
Flvcr1a deficiency promotes heme-based energy metabolism dysfunction in skeletal muscle 113
Clinical applications of mesenchymal stem cells in chronic diseases 113
Difference in Myogenic properties of the human blood-derived stem cells subpopulation isolated from normal and dystrophic tissues 112
Full-Length Dysferlin Expression Driven by Engineered Human Dystrophic Blood-Derived CD133+ Stem Cells 111
Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle 109
Role of Immunoglobulins in Muscular Dystrophies and Inflammatory Myopathies 109
Exon-skipping of dysferlin in CD133+ stem cells isolated from normal and patient affected with dysferlinopathies 107
Combining stem cells and exon skipping strategy to treat dystrophic GRMD dogs 107
Duchenne muscular dystrophy : isolation of CD133-expressing myogenic progenitors from blood and muscle of DMD patients 107
Autologous transplantation of stem cells in DMD 102
Novel insight into stem cell trafficking in dystrophic muscles 100
Advancing Biomarker Discovery and Therapeutic Targets in Duchenne Muscular Dystrophy: A Comprehensive Review 98
Combining Stem Cells and Exon Skipping Strategy to Treat Muscular Dystrophy 83
Stem Cell Therapy for Neuromuscular Diseases 81
Combining Stem Cells and Exon Skipping Strategy to Treat Muscular Dystrophy 78
The immune system in duchenne muscular dystrophy pathogenesis 77
Micro-CT technique for three-dimensional visualization of human stem cells 61
Totale 15.373
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.115
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.115
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021730 0 0 0 0 0 54 101 78 125 39 282 51
2021/20221.157 98 59 31 65 55 79 91 42 178 75 120 264
2022/20231.781 241 179 145 192 195 285 70 136 216 18 64 40
2023/2024966 38 73 44 73 300 56 46 42 10 61 90 133
2024/20252.626 98 198 64 332 206 92 158 268 118 278 205 609
2025/20262.447 517 306 461 382 448 333 0 0 0 0 0 0
Totale 15.373